AMRNAmarin Corporation plc

$338M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M+44.7% YoY

Gross Profit

$35M74.8% margin

Operating Income

-$8M-17.8% margin

Net Income

-$11M-22.9% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$167M

Total Liabilities

$213M

Stockholders' Equity

-$46M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$33M	+44.7%
Gross Profit	$35M	$24M	+45.9%
Operating Income	-$8M	-$15M	+44.7%
Net Income	-$11M	-$16M	+31.4%

AMRN Q3 2017 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena